The positive catalyst for Valeant(VRX) came and went after the company won FDA approval for Brodulamab. Known commercially as SILIQ, the revenue potential for VRX is in the billions.The sales growth will not happen overnight. Once commercially available in 2H/2017, prescription growth will drive the sales. Physicians will prescribe the drug if the efficacy justifies the price. Insurance will pay for the drug if VRX gets the drug down to the $5,000 - $6,000 range. Stellara costs $3,275 a carton, with insurance covering up to $20,000 annually. At Kroger, Target (TGT), or Wal-Mart (WMT), the drug is priced in the range of $9,025 - $9,600.Selling at the lower-priced range for Siliq, VRX could make between $2.0 to $2.5 billion in revenue. This will add meaningfully to earnings for Valeant. Model this revenue level for fiscal 2018 to 2019.Related: Due to high reader interest in Endo International (ENDP), coverage for this generic supplier's turnaround will start at DIY investing. A call for a bottom for Teva Pharma (TEVA) started at DIY, then posted publicly, and is now covered regularly here at Value Stocks. Allergan (AGN), which sold its generics unit, is a buy.Discussion: Will Valeant close higher or lower after it reports earnings? VRX reports on 02/28/2017 at 8:00AM ET. Sign in via StockTwits to comment, below and "like" this post.